Journal Home
Search for

Volume 36, Issue 3, Pages 244-251 (April 2009)


View previous. 4 of 14 View next.

Factors affecting willingness to provide buprenorphine treatment

the BHIVES Collaborative1Julie Netherland, M.S.W.aCorresponding Author Informationemail address, Michael Botsko, M.S.W.b, James E. Egan, M.P.H.b, Andrew J. Saxon, M.D.c, Chinazo O. Cunningham, M.S., M.D.d, Ruth Finkelstein, Sc.D.a, Mark N. Gourevitch, M.D., M.P.H.e, John A. Renner, M.D.fg, Nancy Sohler, Ph.D., M.P.H.h, Lynn E. Sullivan, M.D.i, Linda Weiss, Ph.D.b, David A. Fiellin, M.D.i

Received 18 January 2008; received in revised form 19 May 2008; accepted 22 June 2008. published online 21 August 2008.

Abstract 

Buprenorphine is an effective long-term opioid agonist treatment. As the only pharmacological treatment for opioid dependence readily available in office-based settings, buprenorphine may facilitate a historic shift in addiction treatment from treatment facilities to general medical practices. Although many patients have benefited from the availability of buprenorphine in the United States, almost half of current prescribers are addiction specialists suggesting that buprenorphine treatment has not yet fully penetrated general practice settings. We examined factors affecting willingness to offer buprenorphine treatment among physicians with different levels of prescribing experience. Based on their prescribing practices, physicians were classified as experienced, novice, or as a nonprescriber and asked to assess the extent to which a list of factors impacted their prescription of buprenorphine. Several factors affected willingness to prescribe buprenorphine for all physicians: staff training; access to counseling and alternate treatment; visit time; buprenorphine availability; and pain medications concerns. Compared with other physicians, experienced prescribers were less concerned about induction logistics and access to expert consultation, clinical guidelines, and mental health services. They were more concerned with reimbursement. These data provide important insight into physician concerns about buprenorphine and have implications for practice, education, and policy change that may effectively support widespread adoption of buprenorphine.

a The New York Academy of Medicine, Division of Health Policy, New York, NY, 10029, USA

b The New York Academy of Medicine, Center for Urban Epidemiologic Studies, New York, NY, 10029, USA

c Addictions Care Line VA Puget Sound Health Care System and The Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98108, USA

d Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, 10467, USA

e Division of General Internal Medicine, New York University School of Medicine, New York, NY, 10016, USA

f Boston University School of Medicine, Boston, MA, 02118, USA

g VA Boston Healthcare System, Boston, MA, 02152, USA

h Sophie Davis School of Biomedical Education, City University of New York, City College Campus, 160 Convent Avenue, New York, NY, 10031,USA

i Yale University School of Medicine, New Haven, CT, 06520, USA

Corresponding Author InformationCorresponding author. The New York Academy of Medicine, Division of Health Policy, 1216 5th Ave., New York, NY, 10029, USA. Tel.: +1 212 419 3560; fax: +1 212 876 4220.

1 Collaborative. Yale University School of Medicine (New Haven, CT), El Rio Santa Cruz Neighborhood Health Center (Tucson, AZ), OASIS (Oakland, CA), Oregon Health & Sciences University (Portland, OR), Montefiore Medical Center (New York, NY), University of Miami Medical School (Miami, FL), Miriam Hospital (Providence, RI), UCSF Positive Health Program (San Francisco, CA), Johns Hopkins University (Baltimore, MD), CORE Center (Chicago, IL).

PII: S0740-5472(08)00100-1

doi:10.1016/j.jsat.2008.06.006


View previous. 4 of 14 View next.